Stockreport

Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial

Mustang Bio, Inc.  (MBIO) 
Last mustang bio, inc. earnings: 11/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: mustangbio.com/investor-relations
PDF Trial investigators at City of Hope announce first-reported complete response from a CAR T therapy in a BPDCN patient, additional complete response achieved in AML I [Read more]